1
|
Zhou X, Chen Q, Guo C, Su Y, Guo H, Cao M, Liu Z, Zhang D, Diao N, Fan H, Chen D. CD44 Receptor-Targeted and Reactive Oxygen Species-Responsive H 2S Donor Micelles Based on Hyaluronic Acid for the Therapy of Renal Ischemia/Reperfusion Injury. ACS Omega 2022; 7:42339-42346. [PMID: 36440107 PMCID: PMC9686187 DOI: 10.1021/acsomega.2c05407] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/22/2022] [Accepted: 10/31/2022] [Indexed: 06/16/2023]
Abstract
For the therapy attenuating renal ischemia-reperfusion (IR) injury, a novel drug delivery system was urgently needed, which could precisely deliver drugs to the pathological renal tissue. Here, we have prepared new nanomaterials with a reactive oxygen species (ROS)-responsive hydrogen sulfide (H2S) donor and hyaluronic acid that targets CD44 receptor. The novel material was synthesized and characterized via related experiments. Then, rapamycin was loaded, which inhibited kidney damage. In the in vitro study, we found that the micelles had ROS-responsiveness, biocompatibility, and cell penetration. In addition, the experimental results showed that the intracellular H2S concentration after administration was threefold higher than that of the control group. The western blot assay revealed that they have anti-inflammatory effects via H2S donor blocking the NF-κB signaling pathway. Consequently, the rising CD44 receptor-targeting and ROS-sensitive H2S donor micelles would provide a promising way for renal IR injury. This work provides a strategy for improving ischemia/reperfusion injury for pharmaceuticals.
Collapse
Affiliation(s)
- Xiudi Zhou
- Collaborative
Innovation Center of Advanced Drug Delivery System and Biotech Drugs,
School of Pharmacy, Yantai University, Yantai264005, P. R. China
- Department
of Pharmacy, Binzhou People’s Hospital
Affiliated to Shandong First Medical University, China, Binzhou256600, P. R. China
| | - Qiang Chen
- Collaborative
Innovation Center of Advanced Drug Delivery System and Biotech Drugs,
School of Pharmacy, Yantai University, Yantai264005, P. R. China
| | - Chunjing Guo
- College
of Marine Life Science, Ocean University
of China, Qingdao266003, P. R. China
| | - Yanguo Su
- Collaborative
Innovation Center of Advanced Drug Delivery System and Biotech Drugs,
School of Pharmacy, Yantai University, Yantai264005, P. R. China
| | - Huimin Guo
- Collaborative
Innovation Center of Advanced Drug Delivery System and Biotech Drugs,
School of Pharmacy, Yantai University, Yantai264005, P. R. China
| | - Min Cao
- Collaborative
Innovation Center of Advanced Drug Delivery System and Biotech Drugs,
School of Pharmacy, Yantai University, Yantai264005, P. R. China
| | - Zhongxin Liu
- Collaborative
Innovation Center of Advanced Drug Delivery System and Biotech Drugs,
School of Pharmacy, Yantai University, Yantai264005, P. R. China
| | - Dandan Zhang
- Collaborative
Innovation Center of Advanced Drug Delivery System and Biotech Drugs,
School of Pharmacy, Yantai University, Yantai264005, P. R. China
| | - Ningning Diao
- Collaborative
Innovation Center of Advanced Drug Delivery System and Biotech Drugs,
School of Pharmacy, Yantai University, Yantai264005, P. R. China
| | - Huaying Fan
- Collaborative
Innovation Center of Advanced Drug Delivery System and Biotech Drugs,
School of Pharmacy, Yantai University, Yantai264005, P. R. China
| | - Daquan Chen
- Collaborative
Innovation Center of Advanced Drug Delivery System and Biotech Drugs,
School of Pharmacy, Yantai University, Yantai264005, P. R. China
| |
Collapse
|